Vitamin D and Glomerulonephritis
Abstract
:1. Introduction
2. Vitamin D and VDR in Experimental Models of GN
2.1. Calcitriol Use in Experimental GN
2.2. Paricalcitol Use in Experimental GN
2.3. Maxacalcitol in Experimental GN
2.4. Doxercalciferol in Experimental GN
3. Vitamin D in Children with CKD
3.1. Vitamin D in Children with Idiopathic Nephrotic Syndrome
3.2. Vitamin D-Binding Protein in Children with GN
3.3. Vitamin D Receptor Polymorphism in Children with GN
4. Vitamin D in IgA Nephropathy
5. Vitamin D in Lupus Nephritis
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Floege, J.; Amann, K. Primary glomerulonephritides. Lancet 2016, 387, 2036–2048. [Google Scholar] [CrossRef]
- Saran, R.; Robinson, B.; Abbott, K.C.; Agodoa, L.Y.; Albertus, P.; Ayanian, J.; Balkrishnan, R.; Bragg-Gresham, J.; Cao, J.; Chen, J.L.T.; et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am. J. Kidney Dis. 2017, 69 (Suppl. 1), A7–A8, Erratum in Am. J. Kidney Dis. 2017, 69, 712. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, Y.; DeLuca, H.F. Rat renal 25-hydroxyvitamin D3 1- and 24-hydroxylases: Their in vivo regulation. Am. J. Physiol. 1984, 246, E168–E173. [Google Scholar] [CrossRef] [PubMed]
- Santoro, D.; Sebekova, K.; Teta, D.; De Nicola, L. Extraskeletal Functions of Vitamin, D. Biomed. Res. Int. 2015, 2015, 294719. [Google Scholar] [CrossRef]
- Santoro, D.; Caccamo, D.; Lucisano, S.; Buemi, M.; Sebekova, K.; Teta, D.; De Nicola, L. Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system. Biomed. Res. Int. 2015, 2015, 145828. [Google Scholar] [CrossRef] [Green Version]
- Li, X.-H.; Feng, L.; Yang, Z.-H.; Liao, Y.-H. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. Nephrology 2015, 20, 706–714. [Google Scholar] [CrossRef]
- Dobnig, H.; Pilz, S.; Scharnagl, H.; Renner, W.; Seelhorst, U.; Wellnitz, B.; Maerz, W. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168, 140–149. [Google Scholar] [CrossRef]
- Dattola, A.; Silvestri, M.; Bennardo, L.; Passante, M.; Scali, E.; Patruno, C.; Nisticò, S.P. Role of Vitamins in Skin Health: A Systematic Review. Curr. Nutr. Rep. 2020, 9, 226–235. [Google Scholar] [CrossRef]
- Gembillo, G.; Cernaro, V.; Salvo, A.; Siligato, R.; Laudani, A.; Buemi, M.; Santoro, D. Role of Vitamin D Status in Diabetic Patients with Renal Disease. Medicina 2019, 55, 273. [Google Scholar] [CrossRef] [Green Version]
- Kramer, H.; Berns, J.S.; Choi, M.J.; Martin, K.; Rocco, M.V. 25-Hydroxyvitamin D Testing and Supplementation in CKD: An NKF-KDOQI Controversies Report. Am. J. Kidney Dis. 2014, 64, 499–509. [Google Scholar] [CrossRef] [Green Version]
- Khurana, S.; A Bruggeman, L.; Kao, H.-Y. Nuclear hormone receptors in podocytes. Cell Biosci. 2012, 2, 33. [Google Scholar] [CrossRef] [Green Version]
- Banerjee, S.; Basu, S.; Akhtar, S.; Sinha, R.; Sen, A.; Sengupta, J. Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls. Pediatr. Nephrol. 2020, 35, 447–454. [Google Scholar] [CrossRef]
- De Zeeuw, D.; Remuzzi, G.; Parving, H.-H.; Keane, W.F.; Zhang, Z.; Shahinfar, S.; Snapinn, S.; Cooper, M.E.; Mitch, W.E.; Brenner, B.M. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004, 65, 2309–2320. [Google Scholar] [CrossRef] [Green Version]
- Koivisto, O.; Hanel, A.; Carlberg, C. Key Vitamin D Target Genes with Functions in the Immune System. Nutrients 2020, 12, 1140. [Google Scholar] [CrossRef] [Green Version]
- Monier-Faugere, M.-C.; Mawad, H.; Malluche, H.H. Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal-Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2007, 2, 1255–1260. [Google Scholar] [CrossRef] [Green Version]
- Park, J.; Rhee, C.M.; Lau, W.L.; Kalantar-Zadeh, K. Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr. Vasc. Pharmacol. 2014, 12, 306–312. [Google Scholar] [CrossRef]
- Obi, Y.; Kalantar-Zadeh, K. Yet Another Vitamin D Analogue for the Management of Secondary Hyperparathyroidism: A Triton among the Minnows? Am. J. Nephrol. 2016, 43, 221–224. [Google Scholar] [CrossRef] [Green Version]
- Bikle, D.D.; Abe-Hashimoto, J.; Su, M.-J.; Felt, S.; Gibson, D.F.C.; Pillai, S. 22-Oxa Calcitriol Is a Less Potent Regulator of Keratinocyte Proliferation and Differentiation Due to Decreased Cellular Uptake and Enhanced Catabolism. J. Investig. Dermatol. 1995, 105, 693–698. [Google Scholar] [CrossRef] [Green Version]
- Molina, P.; Górriz, J.L.; Molina, M.D.; Peris, A.; Beltrán, S.; Kanter, J.; Escudero, V.; Romero, R.; Pallardó, L.M. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study. Nephrol. Dial. Transplant. 2014, 29, 97–109. [Google Scholar] [CrossRef] [Green Version]
- Wu, C.-C.; Liao, M.-T.; Hsiao, P.-J.; Lu, C.-L.; Hsu, Y.-J.; Lu, K.-C.; Chu, P. Antiproteinuria Effect of Calcitriol in Patients with Chronic Kidney Disease and Vitamin D Deficiency: A Randomized Controlled Study. J. Ren. Nutr. 2020, 30, 200–207. [Google Scholar] [CrossRef]
- Rodriguez, M.; Munoz-Castaneda, J.R.; Almaden, Y. Therapeutic use of calcitriol. Curr. Vasc. Pharmacol. 2014, 12, 294–299. [Google Scholar] [CrossRef]
- Liu, L.-J.; Lv, J.-C.; Shi, S.-F.; Chen, Y.-Q.; Zhang, H.; Wang, H.-Y. Oral Calcitriol for Reduction of Proteinuria in Patients with IgA Nephropathy: A Randomized Controlled Trial. Am. J. Kidney Dis. 2012, 59, 67–74. [Google Scholar] [CrossRef] [PubMed]
- Fishbane, S.; Chittineni, H.; Packman, M.; Dutka, P.; Ali, N.; Durie, N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial. Am. J. Kidney Dis. 2009, 54, 647–652. [Google Scholar] [CrossRef]
- Alborzi, P.; Patel, N.A.; Peterson, C.; Bills, J.E.; Bekele, D.M.; Bunaye, Z.; Light, R.P.; Agarwal, R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 2008, 52, 249–255. [Google Scholar] [CrossRef] [Green Version]
- De Zeeuw, D.; Agarwal, R.; Amdahl, M.; Audhya, P.; Coyne, D.; Garimella, T.; Parving, H.-H.; Pritchett, Y.; Remuzzi, G.; Ritz, E.; et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010, 376, 1543–1551. [Google Scholar] [CrossRef]
- Zoccali, C.; Curatola, G.; Panuccio, V.; Tripepi, R.; Pizzini, P.; Versace, M.; Bolignano, D.; Cutrupi, S.; Politi, R.; Tripepi, G.; et al. Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension 2014, 64, 1005–1011, Erratum in Hypertension 2014, 64, e48; Erratum in Hypertension 2014, 64, e1. [Google Scholar] [CrossRef] [Green Version]
- Aperis, G.; Paliouras, C.; Zervos, A.; Arvanitis, A.; Alivanis, P. The role of paricalcitol on proteinuria. J. Ren. Care 2011, 37, 80–84. [Google Scholar] [CrossRef]
- De Lorenzo, A.; Salanova, L.; Bomback, A.S.; Moya, M.; Coronel, F.; Bernis, C.; A Sánchez-Tomero, J.; Álvarez, V. Oral paricalcitol as antiproteinuric agent in chronic kidney disease. Nefrologia 2013, 33, 709–715. [Google Scholar]
- Ekart, R.; Bevc, S.; Hojs, R.; Hojs, N. Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients. J. Clin. Pharmacol. 2016, 56, 761–768. [Google Scholar] [CrossRef]
- Brown, J.M.; Secinaro, K.; Williams, J.S.; Vaidya, A. Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: The VALIDATE-D study. BMC Endocr. Disord. 2013, 13, 33. [Google Scholar] [CrossRef] [Green Version]
- Pilz, S.; Verheyen, N.; Grübler, M.R.; Tomaschitz, A.; März, W. Vitamin D and cardiovascular disease prevention. Nat. Rev. Cardiol. 2016, 13, 404–417. [Google Scholar] [CrossRef]
- Li, Y.C.; Qiao, G.; Uskokovic, M.; Xiang, W.; Zheng, W.; Kong, J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 2004, 89–90, 387–392. [Google Scholar] [CrossRef]
- Agarwal, R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin. J. Am. Soc. Nephrol. 2009, 4, 1523–1528. [Google Scholar] [CrossRef] [Green Version]
- Xu, L.; Zhang, P.; Guan, H.; Huang, Z.; He, X.; Wan, X.; Xiao, H.; Li, Y. Vitamin D and its receptor regulate lipopolysaccharide-induced transforming growth factor-β, angiotensinogen expression and podocytes apoptosis through the nuclear factor-κB pathway. J. Diabetes Investig. 2016, 7, 680–688. [Google Scholar] [CrossRef] [Green Version]
- Tan, X.; Wen, X.; Liu, Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol. 2008, 19, 1741–1752. [Google Scholar] [CrossRef] [Green Version]
- Kheirouri, S.; Alizadeh, M. Vitamin D and advanced glycation end products and their receptors. Pharmacol. Res. 2020, 158, 104879. [Google Scholar] [CrossRef]
- Fukami, K.; Taguchi, K.; Yamagishi, S.-I.; Okuda, S. Receptor for advanced glycation endproducts and progressive kidney disease. Curr. Opin. Nephrol. Hypertens. 2015, 24, 54–60. [Google Scholar] [CrossRef]
- García, I.M.; Altamirano, L.; Mazzei, L.; Fornés, M.; Cuello-Carrión, F.D.; Ferder, L.; Manucha, W. Vitamin D receptor-modulated Hsp70/AT1 expression may protect the kidneys of SHRs at the structural and functional levels. Cell Stress Chaperones 2013, 19, 479–491. [Google Scholar] [CrossRef] [Green Version]
- Silvagno, F.; Consiglio, M.; Foglizzo, V.; Destefanis, M.; Pescarmona, G. Mitochondrial Translocation of Vitamin D Receptor Is Mediated by the Permeability Transition Pore in Human Keratinocyte Cell Line. PLoS ONE 2013, 8, e54716. [Google Scholar] [CrossRef] [Green Version]
- McCarron, J.G.; Wilson, C.; Sandison, M.E.; Olson, M.L.; Girkin, J.M.; Saunter, C.; Chalmers, S. From Structure to Function: Mitochondrial Morphology, Motion and Shaping in Vascular Smooth Muscle. J. Vasc. Res. 2013, 50, 357–371. [Google Scholar] [CrossRef] [Green Version]
- Wiggins, R. The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int. 2007, 71, 1205–1214. [Google Scholar] [CrossRef] [Green Version]
- Migliori, M.; Giovannini, L.; Panichi, V.; Filippi, C.; Taccola, D.; Origlia, N.; Mannari, C.; Camussi, G. Treatment with 1, 25-Dihydroxyvitamin D3 Preserves Glomerular Slit Diaphragm-Associated Protein Expression in Experimental Glomerulonephritis. Int. J. Immunopathol. Pharmacol. 2005, 18, 779–790. [Google Scholar] [CrossRef]
- Schwarz, U.; Amann, K.; Orth, S.R.; Simonaviciene, A.; Wessels, S.; Ritz, E. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998, 53, 1696–1705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, C.J.; Zhao, D.; Yin, X.; Zhang, H.; Ma, L.; Chen, J.P.; Liu, C.; Yang, X.P. Effects of 1,25(OH)2D3 on proliferation and apoptosis of human glomerular mesangial cells. Am. J. Transl. Res. 2016, 8, 2659–2666. [Google Scholar] [PubMed]
- Zhao, D.; Zhang, C.-J.; Yang, R.; Chen, J.-P.; Ma, L.; Liu, G.; Yang, X.-P. Effect of 1,25(OH2D3 on the proliferation of human mesangial cells and their expression of Ki67. Genet. Mol. Res. 2017, 16. [Google Scholar] [CrossRef] [PubMed]
- Kim, O. Immunohistochemical study of the expression of α-smooth muscle actin and the proliferation marker Ki-67 of glomerulonephritis. J. Korean Med Sci. 2001, 16, 455–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, X.; Wu, X.; Xiong, L.; Yi, Z.; He, Q.; He, X.; Mo, S. Role of vitamin D3 in regulation of T helper cell 17 and regulatory T-cell balance in rats with immunoglobulin a nephropathy. Iran J. Kidney Dis. 2014, 8, 363–370. [Google Scholar]
- Sonneveld, R.; Ferrè, S.; Hoenderop, J.G.; Dijkman, H.B.; Berden, J.H.; Bindels, R.J.; Wetzels, J.F.; Van Der Vlag, J.; Nijenhuis, T. Vitamin D Down-Regulates TRPC6 Expression in Podocyte Injury and Proteinuric Glomerular Disease. Am. J. Pathol. 2013, 182, 1196–1204. [Google Scholar] [CrossRef]
- Zhang, X.; Song, Z.; Guo, Y.; Zhou, M. The novel role of TRPC6 in vitamin D ameliorating podocyte injury in STZ-induced diabetic rats. Mol. Cell. Biochem. 2015, 399, 155–165. [Google Scholar] [CrossRef]
- Zou, M.-S.; Yu, J.; Zhou, J.-H.; Nie, G.-M.; Ding, D.-S.; Luo, L.-M.; Xu, H.-T.; He, W.-S. 1,25-Dihydroxyvitamin D3 Ameliorates Podocytopenia in Rats with Adriamycin-induced Nephropathy. Intern. Med. 2010, 49, 2677–2686. [Google Scholar] [CrossRef] [Green Version]
- Siligato, R.; Gembillo, G.; Cernaro, V.; Torre, F.; Salvo, A.; Granese, R.; Santoro, D. Maternal and Fetal Outcomes of Pregnancy in Nephrotic Syndrome Due to Primary Glomerulonephritis. Front. Med. 2020, 7, 925. [Google Scholar] [CrossRef]
- Ma, J.; Zhang, B.; Liu, S.; Xie, S.; Yang, Y.; Ma, J.; Deng, Y.; Wang, W.; Xu, L.; Li, R.; et al. 1,25-Dihydroxyvitamin D(3) Inhibits Podocyte uPAR Expression and Reduces Proteinuria. PLoS ONE 2013, 8, e64912. [Google Scholar] [CrossRef] [Green Version]
- Wei, C.; Möller, C.C.; Altintas, M.M.; Li, J.; Schwarz, K.; Zacchigna, S.; Xie, L.; Henger, A.; Schmid, H.; Rastaldi, M.P.; et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 2008, 14, 55–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Masola, V.; Zaza, G.; Onisto, M.; Gambaro, G. Heparanase: Another renal player controlled by vitamin D. J. Pathol. 2016, 238, 7–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garsen, M.; Sonneveld, R.; Rops, A.L.W.M.M.; Huntink, S.; Van Kuppevelt, T.H.; Rabelink, T.J.; Hoenderop, J.G.J.; Berden, J.H.M.; Nijenhuis, T.; Van Der Vlag, J. Vitamin D attenuates proteinuria by inhibition of heparanase expression in the podocyte. J. Pathol. 2015, 237, 472–481. [Google Scholar] [CrossRef]
- Yuan, D.; Fang, Z.; Sun, F.; Chang, J.; Teng, J.; Lin, S.; Liu, X. Effect of Vitamin D and Tacrolimus Combination Therapy on IgA Nephropathy. Med. Sci. Monit. 2017, 23, 3170–3177. [Google Scholar] [CrossRef] [Green Version]
- Yazdani, S.; Poosti, F.; Toro, L.; Wedel, J.; Mencke, R.; Mirković, K.; De Borst, M.H.; Alexander, J.S.; Navis, G.; Van Goor, H.; et al. Vitamin D inhibits lymphangiogenesis through VDR-dependent mechanisms. Sci. Rep. 2017, 7, 44403. [Google Scholar] [CrossRef] [Green Version]
- Ritter, C.; Zhang, S.; Finch, J.L.; Liapis, H.; Suarez, E.; Ferder, L.; Delmez, J.; Slatopolsky, E. Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats. Kidney Blood Press. Res. 2014, 39, 340–352. [Google Scholar] [CrossRef] [PubMed]
- Panizo, S.; Barrio-Vazquez, S.; Naves-Diaz, M.; Carrillo-Lopez, N.; Rodriguez, I.; Fernandez-Vazquez, A.; Valdivielso, J.M.; Thadhani, R.; Cannata-Andia, J.B. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrol. Dial. Transplant 2013, 28, 2735–2744. [Google Scholar] [CrossRef] [Green Version]
- Finch, J.L.; Suarez, E.B.; Husain, K.; Ferder, L.; Cardema, M.C.; Glenn, D.J.; Gardner, D.G.; Liapis, H.; Slatopolsky, E. Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am. J. Physiol. Physiol. 2012, 302, F141–F149. [Google Scholar] [CrossRef] [Green Version]
- Mizobuchi, M.; Morrissey, J.; Finch, J.L.; Martin, D.R.; Liapis, H.; Akizawa, T.; Slatopolsky, E. Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Vitamin D Analog Suppresses the Progression of Renal Insufficiency in Uremic Rats. J. Am. Soc. Nephrol. 2007, 18, 1796–1806. [Google Scholar] [CrossRef] [Green Version]
- Freundlich, M.; Quiroz, Y.; Zhang, Z.; Zhang, Y.; Bravo, Y.; Weisinger, J.R.; Li, Y.C.; Rodriguez-Iturbe, B. Suppression of renin–angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008, 74, 1394–1402. [Google Scholar] [CrossRef] [Green Version]
- Guo, J.; Lu, C.; Zhang, F.; Yu, H.; Zhou, M.; He, M.; Wang, C.; Zhao, Z.; Liu, Z. VDR Activation Reduces Proteinuria and High-Glucose-Induced Injury of Kidneys and Podocytes by Regulating Wnt Signaling Pathway. Cell. Physiol. Biochem. 2017, 43, 39–51, Erratum in Cell. Physiol. Biochem. 2020, 54, 799; Erratum in Cell. Physiol. Biochem. 2020, 54, 1091. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hirata, M.; Makibayashi, K.; Katsumata, K.; Kusano, K.; Watanabe, T.; Fukushima, N.; Doi, T. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol. Dial. Transplant. 2002, 17, 2132–2137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Makibayashi, K.; Tatematsu, M.; Hirata, M.; Fukushima, N.; Kusano, K.; Ohashi, S.; Abe, H.; Kuze, K.; Fukatsu, A.; Kita, T.; et al. A Vitamin D Analog Ameliorates Glomerular Injury on Rat Glomerulonephritis. Am. J. Pathol. 2001, 158, 1733–1741. [Google Scholar] [CrossRef] [Green Version]
- Jeong, K.H.; Asanuma, K.; Lydia, A.; Takagi, M.; Asao, R.; Kodama, F.; Asanuma, E.; Tomino, Y. Combination Therapy with Telmisartan and Oxacalcitriol Suppresses the Progression of Murine Adriamycin Nephropathy. Nephron 2015, 129, 143–154. [Google Scholar] [CrossRef]
- Lydia, A.; Asanuma, K.; Nonaka, K.; Takagi, M.; Jeong, K.-H.; Kodama, F.; Asao, R.; Asanuma, E.; Prodjosudjadi, W.; Tomino, Y. Effects of 22-Oxa-Calcitriol on Podocyte Injury in Adriamycin-Induced Nephrosis. Am. J. Nephrol. 2012, 35, 58–68. [Google Scholar] [CrossRef] [PubMed]
- Brown, A.J.; Finchi, J.; Grieff, M.; Ritter, C.; Kubodera, N.; Nishii, Y.; Slatopolsky, E. The mechanism for the disparate actions of calcit-riol and 22-oxacalcitriol in the intestine. Endocrinology 1993, 133, 1158–1164. [Google Scholar] [CrossRef] [PubMed]
- Hirata, M.; Katsumata, K.; Endo, K.; Fukushima, N.; Ohkawa, H.; Fukagawa, M. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol. Dial. Transplant. 2003, 18, 1770–1776. [Google Scholar] [CrossRef] [Green Version]
- Sanai, T.; Tokumoto, M.; Hirano, T.; Okuda, S. Different effects of 22-oxacalcitriol and calcitriol on the course of experimental chronic renal failure. J. Lab. Clin. Med. 2002, 140, 242–249. [Google Scholar] [CrossRef]
- Matsui, I.; Hamano, T.; Tomida, K.; Inoue, K.; Takabatake, Y.; Nagasawa, Y.; Kawada, N.; Ito, T.; Kawachi, H.; Rakugi, H.; et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol. Dial. Transplant. 2009, 24, 2354–2361. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.X.; Jiang, T.; Shen, Y.; Santamaria, H.; Solis, N.; Arbeeny, C.; Levi, M. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am. J. Physiol. Physiol. 2011, 300, F801–F810. [Google Scholar] [CrossRef] [Green Version]
- Dorotea, D.; Koya, D.; Ha, H. Recent Insights Into SREBP as a Direct Mediator of Kidney Fibrosis via Lipid-Independent Pathways. Front. Pharmacol. 2020, 11. [Google Scholar] [CrossRef]
- Zhang, Y.; Deb, D.K.; Kong, J.; Ning, G.; Wang, Y.; Li, G.; Chen, Y.; Zhang, Z.; Strugnell, S.; Sabbagh, Y.; et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: Strong synergism with AT1 receptor antagonist. Am. J. Physiol. Physiol. 2009, 297, F791–F801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gallagher, J.; Bishop, C.W.; Knutson, J.C.; Mazess, R.B.; DeLuca, H.F. Effects of increasing doses of 1α-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women. J. Bone Miner. Res. 1994, 9, 607–614. [Google Scholar] [CrossRef]
- Miliku, K.; Voortman, T.; Franco, O.H.; McGrath, J.J.; Eyles, D.W.; Burne, T.H.; Hofman, A.; Tiemeier, H.; Jaddoe, V.W. Vitamin D status during fetal life and childhood kidney outcomes. Eur. J. Clin. Nutr. 2016, 70, 629–634. [Google Scholar] [CrossRef] [Green Version]
- Atkinson, M.A.; Melamed, M.L.; Kumar, J.; Roy, C.N.; Miller, E.R.; Furth, S.L.; Fadrowski, J.J. Vitamin D, Race, and Risk for Anemia in Children. J. Pediatr. 2014, 164, 153–158.e1. [Google Scholar] [CrossRef] [Green Version]
- Lerch, C.; Shroff, R.; Wan, M.; Rees, L.; Aitkenhead, H.; Bulut, I.K.; Thurn, D.; Bayazit, A.K.; Niemirska, A.; Canpolat, N.; et al. Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. Nephrol. Dial. Transplant. 2018, 33, 2208–2217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Doyon, A.; Fischer, D.-C.; Bayazit, A.K.; Canpolat, N.; Duzova, A.; Sözeri, B.; Bacchetta, J.; Balat, A.; Büscher, A.; Candan, C.; et al. Markers of Bone Metabolism Are Affected by Renal Function and Growth Hormone Therapy in Children with Chronic Kidney Disease. PLoS ONE 2015, 10, e0113482. [Google Scholar] [CrossRef] [Green Version]
- Naumova, V.I.; Rusnak, F.I.; Vereskova, S.A.; Kutafina, E.K.; Panchenko, E.L. Primenenie vitamina D2 i ego metabolitov pri khronicheskom glomerulonefrite u deteĭ [Use of vitamin D 2 and its metabolites in chronic glomerulonephritis in children]. Pediatriia 1989, 5, 19–22. [Google Scholar]
- Conti, G.; Chirico, V.; Lacquaniti, A.; Silipigni, L.; Fede, C.; Vitale, A.; Fede, C. Vitamin D intoxication in two brothers: Be careful with dietary supplements. J. Pediatr. Endocrinol. Metab. 2014, 27. [Google Scholar] [CrossRef] [PubMed]
- Kalkwarf, H.J.; Denburg, M.R.; Strife, C.F.; Zemel, B.S.; Foerster, D.L.; Wetzsteon, R.J.; Leonard, M.B. Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int. 2012, 81, 690–697. [Google Scholar] [CrossRef] [Green Version]
- Shroff, R.; Wan, M.; Nagler, E.V.; Bakkaloğlu, S.; Fischer, D.-C.; Bishop, N.; Cozzolino, M.; Bacchetta, J.; Edefonti, A.; Stefanidis, C.J.; et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2–5 and on dialysis. Nephrol. Dial. Transplant. 2017, 32, 1098–1113. [Google Scholar] [CrossRef] [Green Version]
- Shroff, R.; Aitkenhead, H.; Costa, N.; Trivelli, A.; Litwin, M.; Picca, S.; Anarat, A.; Sallay, P.; Ozaltin, F.; Zurowska, A.; et al. Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. J. Am. Soc. Nephrol. 2016, 27, 314–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Misra, M.; Pacaud, D.; Petryk, A.; Collett-Solberg, P.F.; Kappy, M. Drug and therapeutics committee of the Lawson Wilkins Pediatric Endocrine Society: Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. Pediatrics 2008, 122, 398–417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wagner, C.L.; Greer, F.R. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008, 122, 1142–1152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noone, D.G.; Iijima, K.; Parekh, R. Idiopathic nephrotic syndrome in children. Lancet 2018, 392, 61–74, Erratum in 2018, 392, 282. [Google Scholar] [CrossRef]
- Nielsen, C.A.; Jensen, J.E.; Cortes, D. Vitamin D status is insufficient in the majority of children at diagnosis of nephrotic syn-drome. Dan. Med. J. 2015, 62, A5017. [Google Scholar]
- Pańczyk-Tomaszewska, M.; Mizerska-Wasiak, M.; Ziółkowska, H.; Adamczuk, D.; Kisiel, A.; Wawer, Z.; Kamińska, A.; Roszkow-ska-Blaim, M. Zasoby witaminy D u dzieci chorobami nerek [Vitamin D status in children with renal diseases]. Med. Wieku Rozwoj. 2013, 17, 306–312. [Google Scholar]
- Zaniew, M.; Jarmoliński, T. Vitamin D status and bone density in steroid-treated children with glomerulopathies: Effect of cholecalciferol and calcium supplementation. Adv. Med. Sci. 2012, 57, 88–93. [Google Scholar] [CrossRef]
- Cantorna, M.T.; Snyder, L.; Lindsay, S.; Yang-Ding, L. Vitamin D and 1,25(OH)2D Regulation of T cells. Nutrients 2015, 7, 3011–3021. [Google Scholar] [CrossRef] [Green Version]
- Sergeev, I.N.; Pletsityĭ, K.D.; Rusnak, F.I.; Spirichev, V.B. Razvitie D-vitaminnoĭ nedostatochnosti i immunologicheskikh narusheniĭ pri glomerulonefrite u deteĭ [Development of vitamin D deficiency and immunologic disorders in children with glomerulone-phritis]. Vopr Pitan. 1990, 4, 28–31. [Google Scholar]
- Cantorna, M.T. Why do T cells express the vitamin D receptor? Ann. N. Y. Acad. Sci. 2011, 1217, 77–82. [Google Scholar] [CrossRef] [PubMed]
- White, P.; Cooke, N. The Multifunctional Properties and Characteristics of Vitamin D-binding Protein. Trends Endocrinol. Metab. 2000, 11, 320–327. [Google Scholar] [CrossRef]
- Newton, D.A.; Baatz, J.E.; Kindy, M.S.; Gattoni-Celli, S.; Shary, J.R.; Hollis, B.W.; Wagner, C.L. Vitamin D binding protein polymorphisms significantly impact vitamin D status in children. Pediatr. Res. 2019, 86, 662–669. [Google Scholar] [CrossRef] [PubMed]
- Madden, K.; Feldman, H.A.; Chun, R.F.; Smith, E.M.; Sullivan, R.M.; Agan, A.A.; Keisling, S.M.; Panoskaltsis-Mortari, A.; Randolph, A.G. Critically Ill Children Have Low Vitamin D–Binding Protein, Influencing Bioavailability of Vitamin D. Ann. Am. Thorac. Soc. 2015, 12, 1654–1661. [Google Scholar] [CrossRef] [Green Version]
- Nykjaer, A.; Dragun, D.; Walther, D.; Vorum, H.; Jacobsen, C.; Herz, J.; Melsen, F.; Christensen, E.I.; E Willnow, T. An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D3. Cell 1999, 96, 507–515. [Google Scholar] [CrossRef] [Green Version]
- Gordon, C.M.; Feldman, H.A.; Sinclair, L.; Williams, A.L.; Kleinman, P.K.; Perez-Rossello, J.; Cox, J.E. Prevalence of Vitamin D Deficiency Among Healthy Infants and Toddlers. Arch. Pediatr. Adolesc. Med. 2008, 162, 505–512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dahl, B.; Schiødt, F.V.; Ott, P.; Wians, F.; Lee, W.M.; Balko, J.; O’Keefe, G.E. Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit. Care Med. 2003, 31, 152–156. [Google Scholar] [CrossRef]
- Bennett, M.R.; Pordal, A.; Haffner, C.; Pleasant, L.; Ma, Q.; Devarajan, P. Urinary Vitamin D-Binding Protein as a Biomarker of Steroid-Resistant Nephrotic Syndrome. Biomark. Insights 2016, 11, 1–6. [Google Scholar] [CrossRef] [Green Version]
- Bennett, M.R.; Pleasant, L.; Haffner, C.; Ma, Q.; Haffey, W.D.; Ying, J.; Wagner, M.; Greis, K.D.; Devarajan, P. A Novel Biomarker Panel to Identify Steroid Resistance in Childhood Idiopathic Nephrotic Syndrome. Biomark. Insights 2017, 12. [Google Scholar] [CrossRef] [PubMed]
- Rajappa, M.; Choudhary, A.; Mohanraj, P.S.; Krishnamurthy, S. Association of Urinary Vitamin D Binding Protein and Neutrophil Gelatinase-Associated Lipocalin with Steroid Responsiveness in Idiopathic Nephrotic Syndrome of Childhood. Saudi J. Kidney Dis. Transplant. 2020, 31, 946–956. [Google Scholar] [CrossRef] [PubMed]
- Gembillo, G.; Cernaro, V.; Siligato, R.; Curreri, F.; Catalano, A.; Santoro, D. Protective Role of Vitamin D in Renal Tubulopathies. Metabolites 2020, 10, 115. [Google Scholar] [CrossRef] [Green Version]
- Chapron, B.D.; Chapron, A.; Phillips, B.; Okoli, M.C.; Shen, D.D.; Kelly, E.J.; Himmelfarb, J.; Thummel, K.E. Reevaluating the role of megalin in renal vitamin D homeostasis using a human cell-derived microphysiological system. Altex 2018, 35, 504–515. [Google Scholar] [CrossRef] [Green Version]
- Santoro, D.; Buemi, M.; Gagliostro, G.; Vecchio, M.; Currò, M.; Ientile, R.; Caccamo, D. Association of VDR gene polymorphisms with heart disease in chronic kidney disease patients. Clin. Biochem. 2015, 48, 1028–1032. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.; Li, A.; Wang, J.; Liu, J.; Han, Y.; Zhang, W.; Li, Y.C.; Zhang, H. Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases. Curr. Med. Chem. 2018, 25, 3256–3271. [Google Scholar] [CrossRef]
- Santoro, D.; Caccamo, D.; Gagliostro, G.; Ientile, R.; Benvenga, S.; Bellinghieri, G.; Savica, V. Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients. J. Nephrol. 2012, 26, 636–644. [Google Scholar] [CrossRef]
- Santoro, D.; Gagliostro, G.; Alibrandi, A.; Ientile, R.; Bellinghieri, G.; Savica, V.; Buemi, M.; Caccamo, D. Vitamin D Receptor Gene Polymorphism and Left Ventricular Hypertrophy in Chronic Kidney Disease. Nutrients 2014, 6, 1029–1037. [Google Scholar] [CrossRef] [Green Version]
- Ozaki, Y.; Nomura, S.; Nagahama, M.; Yoshimura, C.; Kagawa, H.; Fukuhara, S. Vitamin-D receptor genotype and renal dis-order in Japanese patients with systemic lupus erythematosus. Nephron 2000, 85, 86–91. [Google Scholar] [CrossRef]
- Mahyar, A.; Ayazi, P.; Afshar, A.S.; Farivar, T.N.; Sahmani, M.; Oveisi, S.; Shabani, R.; Esmaeili, S. Vitamin D receptor gene (FokI, TaqI, BsmI, and ApaI) polymorphisms in children with urinary tract infection. Pediatr. Res. 2018, 84, 527–532. [Google Scholar] [CrossRef]
- Jafar, T.; Tripathi, G.; Mehndi, A.A.; Mandal, K.; Gulati, S.; Sharma, R.K.; Baburaj, V.P.; Awasthi, S.; Agrawal, S. Vitamin D Receptor Gene Polymorphisms in Indian Children with Idiopathic Nephrotic Syndrome. Int. J. Hum. Genet. 2009, 9, 49–55. [Google Scholar] [CrossRef]
- Al-Eisa, A.; Haider, M.Z. Vitamin D receptor gene TaqI and Apal polymorphisms and steroid responsiveness in childhood idiopathic nephrotic syndrome. Int. J. Nephrol. Renov. Dis. 2016, 9, 187–192. [Google Scholar] [CrossRef] [Green Version]
- Wyatt, R.J.; Julian, B.A. IgA Nephropathy. N. Engl. J. Med. 2013, 368, 2402–2414. [Google Scholar] [CrossRef] [Green Version]
- Li, X.H.; Huang, X.P.; Pan, L.; Wang, C.Y.; Qin, J.; Nong, F.W.; Luo, Y.Z.; Wu, Y.; Huang, Y.M.; Peng, X.; et al. Vitamin D deficiency may predict a poorer outcome of IgA nephropathy. BMC Nephrol. 2016, 17, 164. [Google Scholar] [CrossRef] [Green Version]
- Reich, H.N.; Troyanov, S.; Scholey, J.W.; Cattran, D.C. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 2007, 18, 3177–3183. [Google Scholar] [CrossRef]
- Radhakrishnan, J.; Cattran, D.C. The KDIGO practice guideline on glomerulonephritis: Reading between the (guide) lines—application to the individual patient. Kidney Int. 2012, 82, 840–856. [Google Scholar] [CrossRef] [Green Version]
- Humalda, J.K.; Goldsmith, D.J.A.; Thadhani, R.; De Borst, M.H. Vitamin D analogues to target residual proteinuria: Potential impact on cardiorenal outcomes. Nephrol. Dial. Transplant. 2015, 30, 1988–1994. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Borst, M.H.; Hajhosseiny, R.; Tamez, H.; Wenger, J.; Thadhani, R.; Goldsmith, D.J.A. Active Vitamin D Treatment for Reduction of Residual Proteinuria: A Systematic Review. J. Am. Soc. Nephrol. 2013, 24, 1863–1871. [Google Scholar] [CrossRef]
- Xiaowei, L.; Bo, W.; Li, L.; Peng, Z. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. Int. Urol. Nephrol. 2020, 52, 129–136. [Google Scholar] [CrossRef]
- Szeto, C.C.; Chow, K.M.; Kwan, B.C. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: An uncontrolled trial. Am. J. Kidney Dis. 2008, 51, 724–731. [Google Scholar] [CrossRef]
- Deng, J.; Zheng, X.; Xie, H.; Chen, L. Calcitriol in the treatment of IgA nephropathy with non-nephrotic range proteinuria: A meta-analysis of randomized controlled trials. Clin. Nephrol. 2017, 87, 21–27. [Google Scholar] [CrossRef]
- Mann, M.C.; Hemmelgarn, B.R.; Exner, D.V.; Hanley, D.A.; Turin, T.C.; Wheeler, D.C.; Sola, D.Y.; Ellis, L.; Ahmed, S.B. Vitamin D Supplementation Is Associated With Stabilization of Cardiac Autonomic Tone in IgA Nephropathy. Hypertension 2015, 66. [Google Scholar] [CrossRef] [Green Version]
- DeLuca, G.C.; Kimball, S.M.; Kolasinski, J.; Ramagopalan, S.V.; Ebers, G.C. Review: The role of vitamin D in nervous system health and disease. Neuropathol. Appl. Neurobiol. 2013, 39, 458–484. [Google Scholar] [CrossRef]
- Pilz, S.; Tomaschitz, A.; Drechsler, C.; Dekker, J.M.; März, W. Vitamin D deficiency and myocardial diseases. Mol. Nutr. Food Res. 2010, 54, 1103–1113. [Google Scholar] [CrossRef]
- Zeng, J.; Wen, Q.; Rong, R.; Huang, F.; Yang, Q.; Tang, X.; He, F.; Huang, N.; Yu, X. Vitamin D-Binding Protein Is a Potential Urinary Biomarker of Irbesartan Treatment Response in Patients with IgA Nephropathy. Genet. Test. Mol. Biomarkers 2016, 20, 666–673. [Google Scholar] [CrossRef] [PubMed]
- Shi, M.; Ouyang, Y.; Yang, M.; Yang, M.; Zhang, X.; Huang, W.; Wang, W.; Wang, Z.; Zhang, W.; Chen, X.; et al. IgA Nephropathy Susceptibility Loci and Disease Progression. Clin. J. Am. Soc. Nephrol. 2018, 13, 1330–1338. [Google Scholar] [CrossRef] [PubMed]
- Mo, M.-Q.; Pan, L.; Tan, L.; Jiang, L.; Pan, Y.-Q.; Li, F.-J.; Yang, Z.-H.; Liao, Y.-H. Association between VDR gene FokI polymorphism and renal function in patients with IgA nephropathy. PeerJ 2019, 7, e7092. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, L.; Ma, J.; Zhang, X.; Fan, Y.; Wang, L. Protective role of the vitamin D receptor. Cell. Immunol. 2012, 279, 160–166. [Google Scholar] [CrossRef]
- Rovin, B.; Bomback, A.; Radhakrishnan, J. Chapter 41-Lupus Nephritis. In Chronic Renal Disease; Academic Press: Cambridge, MA, USA, 2015; pp. 501–512. ISBN 9780124116023. [Google Scholar] [CrossRef]
- Alarcón, G.S. Multiethnic lupus cohorts: What have they taught us? Reumatología Clínica 2011, 7, 3–6. [Google Scholar] [CrossRef]
- Sumethkul, K.; Boonyaratavej, S.; Kitumnuaypong, T.; Angthararuk, S.; Cheewasat, P.; Manadee, N.; Sumethkul, V. The predictive factors of low serum 25-hydroxyvitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. Rheumatol. Int. 2013, 33, 1461–1467. [Google Scholar] [CrossRef]
- Lin, T.C.; Wu, J.Y.; Kuo, M.L.; Ou, L.S.; Yeh, K.W.; Huang, J.L. Correlation between disease activity of pediatric-onset systemic lupus erythematosus and level of vitamin D in Taiwan: A case-cohort study. J. Microbiol. Immunol. Infect. 2018, 51, 110–114. [Google Scholar] [CrossRef] [Green Version]
- Yu, Q.; Qiao, Y.; Liu, D.; Liu, F.; Gao, C.; Duan, J.; Liang, L.; Di, X.; Yuan, Y.; Gao, Y.; et al. Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy. Arthritis Res. Ther. 2019, 21, 19. [Google Scholar] [CrossRef] [Green Version]
- Pérez-Ferro, M.; Romero-Bueno, F.I.; Serrano Del Castillo, C.; Mahillo, I.; Alvear, A.; Largo, R.; Herrero-Beaumont, G.; Sánchez-Pernaute, O. A subgroup of lupus patients with nephritis, innate T cell activation and low vitamin D is identified by the enhancement of circulating MHC class I-related chain A. Clin. Exp. Immunol. 2019, 196, 336–344. [Google Scholar] [CrossRef]
- Kizildag, S.; Ates, H.; Kizildag, S. Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann. Hematol. 2010, 89, 1–7. [Google Scholar] [CrossRef]
- Umar, M.; Sastry, K.S.; Chouchane, A.I. Role of Vitamin D Beyond the Skeletal Function: A Review of the Molecular and Clinical Studies. Int. J. Mol. Sci. 2018, 19, 1618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Terrier, B.; Derian, N.; Schoindre, Y.; Chaara, W.; Geri, G.; Zahr, N.; Mariampillai, K.; Rosenzwajg, M.; Carpentier, W.; Musset, L.; et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res. Ther. 2012, 14, R221. [Google Scholar] [CrossRef] [Green Version]
- Zhou, T.B.; Jiang, Z.P.; Lin, Z.J.; Su, N. Association of vitamin D receptor gene polymorphism with the risk of systemic lupus erythematosus. J. Recept Signal. Transduct. Res. 2015, 35, 8–14. [Google Scholar] [CrossRef] [PubMed]
- Emerah, A.A.; El-Shal, A.S. Role of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D level in Egyptian female patients with systemic lupus erythematosus. Mol. Biol. Rep. 2013, 40, 6151–6162. [Google Scholar] [CrossRef] [PubMed]
- Mostowska, A.; Lianeri, M.; Wudarski, M.; Olesińska, M.; Jagodziński, P.P. Vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus. Mol. Biol. Rep. 2013, 40, 803–810. [Google Scholar] [CrossRef] [Green Version]
- Azab, S.F.; Ali, Y.F.; Farghaly, M.A.; Hamed, M.E.; Allah, M.A.; Emam, A.A.; Abdelsalam, N.I.; Hashem, M.I.; Gawish, H.H.; Nabil, R.M.; et al. Vitamin D receptor gene BsmI polymorphisms in Egyptian children and adolescents with systemic lupus erythematosus: A case-control study. Medicine 2016, 95, e5233. [Google Scholar] [CrossRef]
- Imam, A.A.; Ibrahim, H.E.; Farghaly, M.A.A.; Alkholy, U.M.; Gawish, H.H.; Abdalmonem, N.; Sherif, A.M.; Ali, Y.F.; Hamed, M.E.; Waked, N.M.; et al. Vitamin D receptor gene FokI polymorphism in Egyptian children and adolescents with SLE: A case-control study. Lupus 2017, 26, 1426–1434. [Google Scholar] [CrossRef]
- Mahto, H.; Tripathy, R.; Das, B.K.; Panda, A.K. Association between vitamin D receptor polymorphisms and systemic lupus erythematosus in an Indian cohort. Int. J. Rheum. Dis. 2018, 21, 468–476. [Google Scholar] [CrossRef]
- Luo, X.Y.; Yang, M.H.; Wu, F.X.; Wu, L.J.; Chen, L.; Tang, Z.; Liu, N.T.; Zeng, X.F.; Guan, J.L.; Yuan, G.H. Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus 2012, 21, 53–59. [Google Scholar] [CrossRef]
- Sun, J.; Zhang, S.; Liu, J.S.; Gui, M.; Zhang, H. Expression of vitamin D receptor in renal tissue of lupus nephritis and its association with renal injury activity. Lupus 2019, 28, 290–294. [Google Scholar] [CrossRef]
- Brunner, H.I.; Bennett, M.R.; Gulati, G.; Abulaban, K.; Klein-Gitelman, M.S.; Ardoin, S.P.; Tucker, L.B.; Rouster-Stevens, K.A.; Witte, D.; Ying, J.; et al. Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. J. Rheumatol. 2017, 44, 1239–1248. [Google Scholar] [CrossRef] [PubMed]
- Go, D.J.; Lee, J.Y.; Kang, M.J.; Lee, E.Y.; Lee, E.B.; Yi, E.C.; Song, Y.W. Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare. Lupus 2018, 27, 1600–1615. [Google Scholar] [CrossRef]
- Donate-Correa, J.; Domínguez-Pimentel, V.; Méndez-Pérez, M.L.; Muros-de-Fuentes, M.; Mora-Fernández, C.; Martín-Núñez, E.; Cazaña-Pérez, V.; Navarro-González, J.F. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. Mediators Inflamm. 2014, 2014, 670475. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gembillo, G.; Siligato, R.; Amatruda, M.; Conti, G.; Santoro, D. Vitamin D and Glomerulonephritis. Medicina 2021, 57, 186. https://doi.org/10.3390/medicina57020186
Gembillo G, Siligato R, Amatruda M, Conti G, Santoro D. Vitamin D and Glomerulonephritis. Medicina. 2021; 57(2):186. https://doi.org/10.3390/medicina57020186
Chicago/Turabian StyleGembillo, Guido, Rossella Siligato, Michela Amatruda, Giovanni Conti, and Domenico Santoro. 2021. "Vitamin D and Glomerulonephritis" Medicina 57, no. 2: 186. https://doi.org/10.3390/medicina57020186